Luc Therapeutics Information

Luc Therapeutics is developing novel therapeutics targeting the NMDA receptor to treat neuropsychiatric disorders. NMDA receptors are essential components of the brain's cognitive engine, dynamic synaptic plasticity. Luc Therapeutics was formerly known as Mnemosyne Pharmaceuticals. We have designed our discovery enterprise to deliberately tackle the drug discovery obstacles that have contributed to previous high failure rates for neuropsychiatric drugs. We leverage highly experienced medicinal chemistry on the front end, and then electroencephalography (EEG) measurements of translatable, neurophysiological biomarkers of psychiatric disease to power our discovery engine with the strongest possible assets and our preclinical-to-clinical translation with the most useful data. Specifically, the cognitive and functional deficits in schizophrenic patients are correlated with robust deficits in non-invasive EEG measures of brain function. These same measurements can be made in preclinical models, yielding strong translatable biomarkers to use in developing new therapeutics.